Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
55 hedge funds and large institutions have $10.1M invested in Navidea Biopharmaceuticals Inc. in 2016 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 55 → 55 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
24% less capital invested
Capital invested by funds: $13.3M → $10.1M (-$3.19M)
89% less call options, than puts
Call options by funds: $8K | Put options by funds: $75K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
+$146K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$141K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$137K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$99.7K |
| 5 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$79.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$172K |
| 2 |
Goldman Sachs
New York
|
-$163K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
| 4 |
D.E. Shaw & Co
New York
|
-$133K |
| 5 |
Millennium Management
New York
|
-$119K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $1K | – | – | – |
|
|
IA
52
IFP Advisors
Tampa,
Florida
| $1K | – | – | – |
|
53
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
SQA
54
Simon Quick Advisors
Morristown,
New Jersey
| $1K | +$159 | +10 | New |
|
|
55
Barclays
London,
United Kingdom
| – | -$172K | -10,872 | -100% |
|
56
Citadel Advisors
Miami,
Florida
| – | -$63K | -3,426 | Closed |
|
|
SI
57
Stephens Inc
Little Rock,
Arkansas
| – | -$14K | -750 | Closed |
|
|
FAG
58
Financial Advisory Group
Houston,
Texas
| – | -$11K | -625 | Closed |
|
59
Simplex Trading
Chicago,
Illinois
| – | -$2.38K | -150 | Closed |
|
60
JP Morgan Chase
New York
| – | -$2K | -136 | Closed |
|
NAVB Hedge Fund Activity: Q4 2016 in Review
55 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2016, worth a combined $10.1M — down 24% from $13.3M a quarter earlier.
Fund positioning in NAVB was balanced in Q4 2016: 7 funds opened new positions, 7 closed out, 11 added to existing stakes and 13 trimmed.
The largest buyer was Spark Investment Management, adding an estimated $146K. The largest seller was Barclays, cutting an estimated $172K.
- 55 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $10.1M of Navidea Biopharmaceuticals Inc. stock for Q4 2016, down 24% quarter-over-quarter.
- 7 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2016 and 7 closed out, a net change of 0 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2016 was Spark Investment Management, an estimated $146K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q4 2016 was Barclays, an estimated $172K sold.
Based on aggregated 13F filings for Q4 2016.